Background-Cardiovascular disease continues to cause significant morbidity, mortality, and impaired quality of life, with unrealized health gains from the underuse of available evidence. The Transitions, Risks, and Actions in Coronary Events Center for Outcomes Research and Education (TRACE-CORE) aims to advance the science of acute coronary syndromes by examining the determinants and outcomes of the quality of transition from hospital to community and by quantifying the impact of potentially modifiable characteristics associated with decreased quality of life, rehospitalization, and mortality. Methods and Results-TRACE-CORE comprises a longitudinal multiracial cohort of patients hospitalized with acute coronary syndromes, 2 research projects, and development of a nucleus of early stage investigators. We are currently enrolling 2500 adults hospitalized for acute coronary syndromes at 6 hospitals in the northeastern and southeastern United States. We will follow these patients for 24 months after hospitalization through medical record abstraction and 5 patient interviews focusing on quality of life, cardiac events, rehospitalizations, mortality, and medical, behavioral, and psychosocial characteristics. The Transitions Project studies determinants of and disparities in outcomes of the quality of patients' transition from hospital to community. Focusing on potentially modifiable factors, the Action Scores Project will develop and validate action scores to predict recurrent cardiac events, death, and quality of life, describe longitudinal variation in these scores, and develop a dashboard for patient and provider action on the basis of these scores. Conclusions-In TRACE-CORE, sound methodologic principles of observational studies converge with outcomes and effectiveness research approaches. We expect that our data, research infrastructure, and research projects will inform the development of novel secondary prevention approaches and underpin the careers of cardiovascular outcomes researchers.
Methods and Design
TRACE-CORE is a Center for Cardiovascular Outcomes Research with the following research and training aims: (1) to establish a longitudinal cohort of patients hospitalized with ACS, (2) the Transitions Project, (3) the Actions Scores Project, and (4) the development of a nucleus of early stage investigators. Table 1 details the aims and associated research activities and hypotheses. TRACE-CORE uses a multisite prospective cohort design to follow an eventual total of 2500 individuals hospitalized with ACS for 24 months after hospital discharge. Data are collected through patient interviews during hospitalization and at 1, 3, 6, and 12 months after hospital discharge and abstraction of medical records through 24 months postdischarge. The study is led and coordinated by faculty and staff at the University of Massachusetts Medical School (UMMS; principal investigator: C.I.K.). The Committee for the Protection of Human Subjects at UMMS and Institutional Review Boards at each participating recruitment site approved this study. All participants provide informed consent.
Study Sites
There are 6 individual recruitment and data collection sites. In Massachusetts, the participating sites are the 2 teaching hospitals (University and Memorial) that comprise the UMass Memorial Medical Center (UMMMC), a large academic medical center, and St. Vincent Hospital, a large community hospital. These 3 hospitals provide services to the vast majority of residents hospitalized with ACS in central Massachusetts. In Georgia, the participating sites are Northside and Piedmont Hospitals, community hospitals in Atlanta affiliated with Kaiser Permanente Georgia, and the Medical Center of Central Georgia, the major cardiac referral hospital for central and southern Georgia, located in Macon. These sites serve a heterogeneous patient population, represent both community hospitals and academic medical centers, and were purposely selected for their ethnic/racial, socioeconomic, urban/rural, and other sociodemographic diversity.
Participant Screening, Eligibility Determination, and Enrollment
Active surveillance for case identification is done to identify eligible patients admitted to participating medical centers. Site coordinators review computerized hospital admission logs on a daily basis for a standardized list of admission diagnoses related to ACS. The site coordinators also review lists for planned percutaneous coronary intervention/coronary artery bypass graft procedures, Cardiac Catheterization Laboratory lists, lists by hospital floor, and lists of patients with elevated troponin levels to ensure that all potentially eligible patients are identified. Site coordinators then use additional medical record information (ie, laboratory records, ECG reports, and history and physical examination findings) to confirm the patient's eligibility status ( Table 2) . Because of rapidly changing criteria for acute hospitalization, we also include patients admitted for elective PCI or CABG, provided that they have symptoms of acute coronary ischemia within 72 hours of admission. Inclusion criteria include symptoms consistent with ACS and 1 of the following: serial EKG changes, elevated biomarkers of myocardial necrosis, or cardiac catheterization findings revealing >70% stenosis in a coronary artery ( Table 2 ). After discharge, each participant's discharge summary is reviewed to confirm an ACS diagnosis of either unstable angina, ST-elevation myocardial infarction (STEMI), or non-ST-elevation myocardial infarction (non-STEMI). Questionable cases are adjudicated by 2 cardiologists. After eligibility confirmation, a study-trained research assistant approaches the patient in the hospital to introduce them to the study. During this interaction, the research assistant completes the Confusion Assessment Method (CAM) 8 to screen for delirium and determine the patient's ability to provide informed consent. After obtaining Table 1 
. Aims and Associated Activities and Hypotheses of TRACE-CORE
Aim 1-To recruit and follow for 2 y a multiracial cohort of 2500 adults residing in urban, suburban, and rural areas of Massachusetts and Georgia hospitalized at 6 community teaching and nonteaching hospitals.
Recruit and enroll patients, conduct baseline in-person interview, and review inpatient medical records of this index ACS hospitalization.
Follow patients for 2 y, reviewing rehospitalization records and electronically available outpatient records.
Conduct follow-up interviews at 1, 3, 6, and 12 mo after discharge from the index hospitalization.
Aim 2-Transitions project
Engage a technical advisory panel in consensus building to assist in the selection and evaluation of measures of transition quality focused on the first 90 d after discharge, extending beyond existing systems limited to the discharge process.
Characterize the transition from hospital to community for ACS patients.
Examine the determinants and outcomes for transition care quality, testing the following hypotheses: H1: Better transition quality is associated with improved postdischarge quality of life. H2: Better transition quality is associated with longer time to first emergency department visit or rehospitalization.
H3: Patients who are potentially vulnerable due to (1) race/ethnicity, (2) socioeconomic status, (3) total morbidity burden, or (4) cognitive status will have worse transition quality.
H4: Transition quality partially mediates observed disparities in outcomes for vulnerable patients.
Aim 3-Action Scores Project
Develop and validate 2 kinds of "CVD Action Scores" to predict (1) recurrent cardiac events or death and (2) quality of life.
Describe longitudinal variation in the Action Scores over 2 y and test the hypothesis:
H5: Observed health disparities for populations vulnerable because of (a) race/ethnicity, (b) socioeconomic status, (c) total morbidity burden, or (d) cognitive status would be reduced if actions identified in the Action Scores were taken by patients and providers.
Develop a dashboard for CVD action based on regression models underlying the Action Scores.
Aim 4-Develop a nucleus of early stage investigators (ESIs)
Implement structured mentoring for the ESIs.
Engage the ESIs as co-Principal Investigators in the 2 research projects (Aims 2 and 3), and encourage them to take leadership roles in the design and implementation of the cohort (Aim 1). 
Data Collection
TRACE-CORE's rich data are derived from patient interviews and abstraction of participants' medical records; measures are described in more detail below and are outlined in Table 3 . The computer-assisted 60-minute baseline interview is conducted in person during the patient's index hospitalization for ACS or by phone within 72 hours of discharge by trained interviewers. Computer-assisted 45-to 60-minute follow-up telephone interviews at 1, 3, 6, and 12 months after hospital discharge for participants at all sites are conducted by trained interviewers at the UMMS. At least 10 calling attempts are made to each participant for each assessment at varying times during weekdays and weekends to maximize interview completion. Baseline and follow-up interviews are conducted using systems that allow skip patterns on the basis of responses to previous questions within the current interview and from previous interviews, thus reducing participant burden by easily avoiding redundant or irrelevant questions. Participants receive monetary incentives in the form of gift cards for completing study interviews; total incentives for completing the study range from $45 to $75 on the basis of differences in living costs and IRB-designated guidelines at each site. Trained staff at each study site abstract participants' medical records into an online data entry system with built-in quality and consistency checks using standardized procedures. There are 3 components to medical record data collection: (1) medication use is abstracted from the medical record soon after discharge and is used to prepopulate medication information for the 1-month follow-up interview; (2) a comprehensive baseline medical record abstraction occurs postdischarge; and (3) follow-up medical record reviews occur after events reported by participants during the follow-up phone interviews (eg, rehospitalization) and at 6, 12, 18, and 24 months to check for hospitalizations at the study hospitals (Table 3) . Source data, such as laboratory and medication records, are used in preference to interpreted data, such as those summarized in physician or nursing progress notes. For information that has been interpreted by a care provider, the note that is deemed most complete or the note that was written closest in time to the ACS event is used when there are discrepancies. Study staff conduct duplicate abstractions on 5% of randomly selected charts to determine inter-rater reliability of medical record abstractions. Additionally, during site visits, audits are conducted of all study-related documentation to ensure appropriate record keeping and adherence to established protocols.
In addition, a subsample of participants from central Massachusetts also have blood samples drawn and stored for future use in ancillary studies. This is made possible through a collaboration between the TRACE-CORE investigators and the UMMS's Conquering Diseases Biorepository Core funded through the University of Massachusetts' Clinical and Translational Science Award (CTSA).
Measures
Data collected for use by both the Transitions and Action Scores projects include transition quality, quality of life, clinical outcomes, and medical, behavioral, psychosocial, and demographic characteristics. A list of domains measured along with the mode and timing of data collection and projects utilizing each measure are shown in Table 3 .
Our main measure of care transitions is the Care Transition Measure (CTM15), a 15-item measures assessing the quality of care transitions from the patient's perspective. 9 The measure has good psychometric properties and has been demonstrated to have predictive validity for rehospitalizations. 9 During each follow-up interview, participants report the quality of their care transition for their most recent hospitalization by completing the 3-item Care Transition Measure (CTM3). 10 We also include several questions to evaluate the general discharge environment context, including questions on hearing and visual impairment and level of caregiving support, including unmet caregiving needs.
Quality of life is an important outcome for both the Transitions Project and the Action Scores Project (Table 3) 
of the SF-36. 11 The SF-36 has been recommended as a most appropriate generic quality of life instrument for patients with cardiovascular disease. To reduce participant burden, the 12-item version (SF12) is collected during the 12-month interview. 12 Disease-specific quality of life is measured by the Seattle Angina Questionnaire(SAQ), 13 and the disease impact scale (DIS-7). The SAQ is a 19-item questionnaire measuring 5 dimensions of coronary artery disease: physical limitation, angina stability, angina frequency, treatment satisfaction, and disease perception. 13 The DIS-7 is a newly developed scale measuring the diseasespecific impact on quality of life; this measure is standardized to enable comparisons across different therapeutic areas. The DIS-7 includes an item assessing the global impact of ACS on the patient's wellbeing and 6 items measuring fatigue, general health outlook and worry, mental health, physical functioning, role participation, and social activities (personal communication with Dr John E. Ware, Jr., August 8, 2011). Participants self-report emergency room visits and readmissions during the follow-up interviews. We confirm these reports when possible by reviewing admission logs at study hospitals. Medical records reviewed at 6, 12, 18, and 24 months after discharge from the index hospitalization also provide data on timing and reason for rehospitalization. All-cause mortality will be ascertained from proxy report when attempting follow-up interviews and review of medical records and local, state, and national vital statistics records.
Behavioral characteristics are assessed during the baseline and follow-up interviews (Table 3) . Frequency, intensity, and duration of physical activity is assessed through a series of questions used in the Women's Health Initiative. 15 Diet is briefly assessed using Starting the Conversation, an 8-item simplified food frequency questionnaire designed for use in primary care and health-promotion settings. 16 Alcohol consumption, smoking, and use of smokeless tobacco products are assessed using items from Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH). 7 Participants report weight changes occurring between follow-up interviews. At the 1and 3-month interviews we ask participants whether a doctor or nurse suggested that they make a series of lifestyle changes, whether they intend to make these changes, and how confident they feel in their ability to make these changes. At every interview, medication adherence is assessed by the Morisky scale; 17 cost-related nonadherence is assessed at baseline and 12 months using questions included in the Medicare Current Beneficiary Survey. 18 We assess several psychosocial characteristics for use in both projects. Cognitive impairment is measured using the Telephone Interview for Cognitive Status (TICS), a telephone assessment of cognitive function. 19 At baseline and 1 month, participants complete the 9-item Patient Health Questionnaire (PHQ-9), which assesses depressive symptoms and can be used to make criteria-based diagnoses of depressive disorders, 20 and the Generalized Anxiety Disorder (GAD7), a 7-item valid scale for identifying probable cases of generalized anxiety disorder. 22 At later interviews, the 2-item Patient Health Questionnaire (PHQ2) and Generalized Anxiety Disorder (GAD2) provide brief screens for depression and anxiety, respectively. 21, 23 We have included a set of measures assessing patients' engagement in their health care: a 5-item scale measuring trust in physicians, 24 the Patient Activation Measure (PAM6) which assesses patient knowledge, skill, and confidence for self-management, 25 preferences for shared decision making between the patient and provider, 26 and brief screens of low health literacy 28 and numeracy. 27 Also included in baseline and follow-up interviews are measures of perceived stress and social support: the Perceived Stress Scale (PSS4), a 4-item measure designed to measure the degree to which situations in one's life are appraised as stressful, 29 6 questions from the Medical Outcomes Study Social Support Survey, 30 and the 6-item Lubben Social Network Scale (LSNS6) which asks about social ties to family and friends. 31
Methods and Activities Specific to the Research Projects

Transitions Project
Activities and hypotheses to be tested as part of the Transitions Project are listed in Table 1 . We have engaged an expert advisory panel to determine critical measures of transition quality, and we aim to describe transitions from the hospital to the community for ACS patients and to examine the determinants and outcomes of care transition quality. The panel comprised 6 international experts in transitional care and included cardiologists, health economists, and health services researchers. The group provided feedback on items from the proposed survey assessing transitional care and quality and identified areas of deficiency. In addition to the Care Transition Measure 9 as our main measure of transition quality, based on panel recommendations, we included several psychosocial measures in the baseline and 1-month interviews (eg, depression and cognitive impairment) and consider several patient clinical characteristics that have not been previously examined with respect to care transitions such as vision or hearing impairment. Potential behavioral and psychosocial determinants of transition quality were also discussed by the panel and are outlined in Table 3 . We will also examine outcomes of transition quality, including quality of life (as measured by the SF-36, 11 the Seattle Angina Questionnaire (SAQ), 13 and the disease-specific impact scale) and rehospitalizations. The expert advisory panel will convene again after the completion of data collection activities to discuss the findings regarding transition quality and the implications of these findings.
Action Scores Project
Activities and hypotheses to be tested as part of the Action Scores Project are listed in Table 1 . We will develop 2 sets of Action Scores to predict (1) recurrent cardiac events and all-cause mortality and (2) quality of life as measured by the physical and mental component scores (PCS and MCS) of the SF-36, 11 SAQ, 13 and the disease-specific impact scale. We will build on the Global Registry of Acute Coronary Events (GRACE) model for predicting death within 6 months after discharge for ACS; this risk score includes only factors not modifiable by the patient or his/her healthcare team (ie, age, medical history, clinical presentation, and in-hospital cardiac procedures). 32 Action Scores will be based on statistical models that include both these nonmodifiable factors and modifiable factors, but with particular emphasis on factors potentially amenable to intervention (eg, physical activity, diet, weight, smoking cessation, medication adherence). We also include factors that may not be amenable to intervention (eg, cognitive impairment, low health literacy, vision, or hearing impairment), but might provide information on subgroups where targeted interventions would be most effective. Additional behavioral and psychosocial predictors are listed in Table 3 .
We will use procedures widely accepted for clinical prediction rules 33, 34 to develop these Action Scores. We will develop Action Scores on the basis of information from patient interviews during hospitalization and at 1 and 3 months postdischarge. If new events occur after the index ACS, we will account for the fact that more recent events affect future risk more than remote events. We will develop score sheets based on the β coefficients of the variables included in the final regression model for use in clinical practice. Next, we will describe longitudinal variation in the Action Scores and test the hypothesis (Table 1 ). Finally, we will develop a dashboard (control panel) for CVD action that represents the blueprint of a future tailored measurement system. Calculations based on our regression models will populate the dashboard. The dashboard is intended as graphical display of factors potentially modifiable by patients and providers; interface and content of the dashboard will be developed after the completion of the first stages of this project.
Development of Early Stage Investigators
The fourth aim of TRACE-CORE is the development of 4 early stage investigators (M.E.W., J.S.S., M.D.A., D.D.M.) as cardiovascular outcomes researchers (Table 1) . By implementing structured mentoring, engaging them as Co-PIs of the two research projects, and assisting them in preparing K-and R-type applications, TRACE-CORE goes beyond the experiential learning common to many large research studies. The early stage investigators have leadership roles in the design and implementation of the longitudinal cohort and in convening the national consensus panel to discuss measures of transition quality. These investigators will lead the writing groups of manuscripts detailing the main results of the 2 research projects and other important manuscripts. e49
Potential for Ancillary Studies
The rich clinical and patient-reported data collected in TRACE-CORE provide a valuable resource to the community of cardiovascular outcomes researchers. Plasma, DNA, and RNA are also being obtained from TRACE-CORE participants hospitalized at the UMMMC in Worcester, MA. TRACE-CORE aims and projects do not include analysis of these biological samples; these data are collected to facilitate future ancillary studies. Also possible are studies linking the rich clinical and patient-reported TRACE-CORE data to claims data such as that from Medicare, or to US Census or geographic information system data. We welcome proposals for ancillary studies not only from TRACE-CORE investigators but also from investigators at other institutions.
Conclusions
TRACE-CORE builds on the NHLBI's strong history of longitudinal observational research [5] [6] [7] by adding a dimension of patient-reported outcomes collection and of quality of healthcare measurement that bridges epidemiology with outcomes and effectiveness research. Using data from the large, diverse cohort of adults with ACS established as part of this Center for Cardiovascular Outcomes Research, the 2 research projects aim to advance the science of prognosis post-ACS by increasing our understanding of the determinants and outcomes of the quality of the transition from hospital to community, and by quantifying the impact of potentially modifiable characteristics associated with decreased quality of life, rehospitalization, and mortality.
The Transitions Project aims to enhance our understanding of the determinants and outcomes of ACS-specific transition quality over the extended postdischarge period. Shortened hospital stays and fragmented care across settings make the transition after hospitalization for ACS a high-risk period. Problematic transitional care includes poor patient readiness, conflicting advice for self-management, minimal patient input into care planning, medication errors, inaccurate information transfer, and inadequate follow-up. [35] [36] [37] [38] Care coordination interventions may be ineffective in the absence of a transitional care component beyond the time of discharge. 39 The Transitions Project will address important gaps in the literature by characterizing the transition from the hospital to the community. We will examine determinants and outcomes of transition care quality, especially among patients vulnerable to poor-quality transitions as a result of race/ethnicity, socioeconomic status, comorbidities, or psychosocial factors such as cognitive impairment, enhancing our understanding of the complex relationship between transitional care and ACS health disparities. [40] [41] [42] By examining novel patient factors, such as cognitive impairment and comorbidity burden, as risk factors for poor transition quality, the Transitions Project may identify groups of patients who require tailored discharge planning or modified follow-up schedules, thus laying the groundwork for the development of interventions to improve transitional care for patients following ACS.
The Action Scores project aims to advance the science of CVD risk assessment by separating modifiable from nonmodifiable risk, and by predicting the important patient-centered outcome of quality of life. The development of models to predict quality of life after discharge for ACS represents one of the unique contributions of TRACE-CORE to the literature. We will build on the model predicting prognosis in the GRACE study 32 by including factors potentially amenable to intervention, and by constructing risk scores to predict rehospitalization and quality of life after discharge for ACS. The Action Scores may also identify patterns of suboptimal management in particularly vulnerable groups, the remediation of which could lead to reducing health disparities. To help guide provider and patient action, we will develop a dashboard (control panel); dashboards are increasingly being used as a way to summarize complex data to improve patient care. 43, 44 The value of the Action Scores will be enhanced by a userfriendly measurement system allowing for recommendations for action, and the final product of this project will be a roadmap for such a system to be further developed in future work.
In summary, TRACE-CORE represents a convergence of (1) sound principles of primary data collection for observational studies and their analyses, which have been developed through decades of NHLBI-funded large epidemiological cohort studies and (2) outcomes and effectiveness research approaches to collecting and interpreting patient-centered outcomes data. We expect that our data, research infrastructure, and results of our 2 research projects will improve our understanding of the natural history of patients hospitalized with ACS, lead to the development of novel secondary prevention approaches, and underpin the careers of CVD outcomes researchers.
